Eli Lilly's late-stage trial results for Foundayo are notable. The company said the obesity pill significantly reduced the severity of obstructive sleep apnea in patients with obesity, and it plans to file for U.S. approval for moderate-to-severe OSA in adults who are obese or overweight by the end of the year. For a condition that the report says affects nearly 1 billion adults globally, and that most people with it have never been diagnosed, a daily pill would be a meaningful alternative to machines.
The numbers are encouraging in places. In patients not using positive airway pressure therapy, the average apnea-hypopnea index fell by 21.1 events per hour more than under placebo, and the overall AHI reduction was 43.8% compared with 6.3% for placebo. Among patients using PAP, the reduction was about 27.5% versus 3% for placebo. Lilly also reported roughly 11% average weight loss across groups at 52 weeks.
But the safety figures deserve as much attention as the efficacy figures. Around 12% of patients not using PAP discontinued Foundayo because of side effects, compared with 3.8% on placebo. Among patients using both Foundayo and PAP, 6.8% stopped because of side effects, compared with 0.6% on placebo. The report says the most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, and were generally mild to moderate. Those are the kinds of reactions that determine whether people stay on a drug long enough to benefit from it.
The report also notes that the response was not universal. Lilly said 31.5% of patients in the non-PAP group met criteria for remission or improvement to mild OSA, and 19.6% of those on Foundayo plus PAP did. That means most participants did not reach that threshold, even though their breathing measures improved. Patients and doctors will need to weigh those averages against individual outcomes.
Regulators should review the full trial data closely when the filing arrives, particularly the discontinuation rates and long-term tolerability. Lilly should publish clear, plain-language summaries of the trial for patients, not only investor-facing releases. If Foundayo is approved, patients and clinicians deserve a straightforward account of who benefits most, who is likely to quit, and what monitoring is required.